Biotech Stocks At 52-Week Highs - PGEN, EXEL, TWST, HNGE, PBYIrttnews·Oct 1 at 09:11 AMEXEL+0.78%HNGE-0.28%
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High - Should You Buy?Market Beat·Sep 30 at 04:21 PMEXEL+0.78%
Exelixis, Inc. $EXEL Shares Bought by Envestnet Asset Management Inc.Market Beat·Sep 28 at 07:21 AMEXEL+0.78%
Adagene CEO Makes Bold Insider Move With Fresh Stock PurchaseTip Ranks·Sep 18 at 02:05 AMADAG-2.73%EXEL+0.78%
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3BMarket Beat·Sep 17 at 03:03 PMEXEL+0.78%
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp HurdleMarket Beat·Sep 15 at 11:03 AMEXEL+0.78%
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target ReaffirmedTip Ranks·Sep 14 at 02:45 PMEXEL+0.78%
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer FranchisesMarket Beat·Sep 14 at 08:02 AMEXEL+0.78%
Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)businessinsider·Sep 12 at 11:46 PMINSM+2.33%SPCX+7.35%
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold RatingTip Ranks·Sep 12 at 05:45 PMEXEL+0.78%
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs Inbenzinga_article·Sep 11 at 06:02 PMEXEL+0.78%
Exelixis NDA review for zanzalintinib plus atezolizumab extended; PDUFA date moved to Mar 3, 2027TradingView·Sep 11 at 11:03 AMEXEL+0.78%
Adagene’s Platform Partnerships and Muzastotug Catalysts Support Buy Rating, Price Target Unchanged at $8Tip Ranks·Sep 10 at 03:05 PMADAG-2.73%EXEL+0.78%
Adagene hits preclinical milestone for Exelixis-partnered XB404 SAFEbody ADC, triggers $2 million paymentPUBT·Sep 9 at 12:02 PMEXEL+0.78%ADAG-2.73%
EXEL: CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plansQuartr·Sep 8 at 04:45 PMEXEL+0.78%
